| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
iNtRON Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,490.00 |
| 52 Week High | ₩12,470.00 |
| 52 Week Low | ₩5,250.00 |
| Beta | 0.49 |
| 11 Month Change | 2.53% |
| 3 Month Change | -0.46% |
| 1 Year Change | 6.92% |
| 33 Year Change | -71.90% |
| 5 Year Change | -36.68% |
| Change since IPO | 62.25% |
Recent News & Updates
Recent updates
We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt
May 03
We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability
Mar 24Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?
Feb 28iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?
Jan 31
iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet
Jan 05What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You
Dec 10iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years
Nov 26Shareholder Returns
| A048530 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 20.6% | 3.1% | -3.1% |
| 1Y | 6.9% | 26.7% | -2.4% |
Return vs Industry: A048530 underperformed the KR Biotechs industry which returned 26.7% over the past year.
Return vs Market: A048530 exceeded the KR Market which returned -2.4% over the past year.
Price Volatility
| A048530 volatility | |
|---|---|
| A048530 Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A048530 has not had significant price volatility in the past 3 months.
Volatility Over Time: A048530's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 81 | Alek Yoon | www.intron.co.kr |
iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.
iNtRON Biotechnology, Inc. Fundamentals Summary
| A048530 fundamental statistics | |
|---|---|
| Market cap | ₩215.41b |
| Earnings (TTM) | -₩8.52b |
| Revenue (TTM) | ₩9.42b |
22.9x
P/S Ratio-25.3x
P/E RatioIs A048530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A048530 income statement (TTM) | |
|---|---|
| Revenue | ₩9.42b |
| Cost of Revenue | ₩3.83b |
| Gross Profit | ₩5.59b |
| Other Expenses | ₩14.11b |
| Earnings | -₩8.52b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -256.63 |
| Gross Margin | 59.34% |
| Net Profit Margin | -90.40% |
| Debt/Equity Ratio | 0% |
How did A048530 perform over the long term?
See historical performance and comparison